Amgen ISS

Quote
















anonymous said:
They are supposed to sell Aimovig but they do not. They do nothing for Aimovig but win trips and money from Neuro reps. Worthless for Aimovig help.
Click to expand...

Yeah…..they are winning trips for the work NUBU is doing on a 20% weighted product….right. Neuro drives the market for Aimovig. Always has and always will. PCP adds to the bottom line. Let’s not get it twisted.

ISS has Repatha/Otezla/Aimovig.

Repatha is one of the highest priority brands at Amgen. A majority of the growth with Repatha now comes from PCP. At least that was the case 2nd half of 2021 and is expected to continue. Otezla is very profitable. Aimovig….well….the marketplace has gotten very crowded and ISS’ time is better spent on Repatha and Otezla….where the growth is projected to come from. But Aimovig still is a helluva medicine that performs well.
 




anonymous said:
Yeah…..they are winning trips for the work NUBU is doing on a 20% weighted product….right. Neuro drives the market for Aimovig. Always has and always will. PCP adds to the bottom line. Let’s not get it twisted.

ISS has Repatha/Otezla/Aimovig.

Repatha is one of the highest priority brands at Amgen. A majority of the growth with Repatha now comes from PCP. At least that was the case 2nd half of 2021 and is expected to continue. Otezla is very profitable. Aimovig….well….the marketplace has gotten very crowded and ISS’ time is better spent on Repatha and Otezla….where the growth is projected to come from. But Aimovig still is a helluva medicine that performs well.
Click to expand...

A majority of Repatha growth comes from pcps?!?! HAHAHA that’s absolutely laughable! My Repatha contribution from PCPs is 8%! And because of that idiotic pcp percentage in the incentive plan for cardiology reps, we get penalized for that! Total bs! The cardiology scripts carry the ISS teams! And the ISS team gets paid more per script! It’s a joke!
 




anonymous said:
A majority of Repatha growth comes from pcps?!?! HAHAHA that’s absolutely laughable! My Repatha contribution from PCPs is 8%! And because of that idiotic pcp percentage in the incentive plan for cardiology reps, we get penalized for that! Total bs! The cardiology scripts carry the ISS teams! And the ISS team gets paid more per script! It’s a joke!
Click to expand...

EXACTLY

the cardiology team carries ISS with Repatha and the NuBu team carries ISS with Aimovig. They are paid for what WE do.
 








anonymous said:
EXACTLY

the cardiology team carries ISS with Repatha and the NuBu team carries ISS with Aimovig. They are paid for what WE do.
Click to expand...

not true in all cases, my Repatha PCP contribution was between 55-60% for the past 2 years and was top 10 in country in volume… my PCP unit goal was higher than my cardiology unit goal the past 3 quarters and my percent unit growth was more than triple my CV team’s in that same time frame…

the real problem is, our territories don’t line up 100%, so if you (as a CV rep) overlap with 2-3 ISS reps, you blame all ISS reps as being awful when PCP doesn’t perform… same thing happens on ISS team, when we overlap w 2-3 CV territories, we blame all CV reps when the cardiologists don’t perform. Truth is, there are pockets where both teams are doing well and both teams could improve… If Amgen were smart, they would fix this issue and not have territory maps looking like Venn Diagrams, that would increase accountability significantly. But then again, no one wants that here, everyone wants a back pocket excuse when they don’t do well rather than owning it. That’s the real problem.
 




anonymous said:
not true in all cases, my Repatha PCP contribution was between 55-60% for the past 2 years and was top 10 in country in volume… my PCP unit goal was higher than my cardiology unit goal the past 3 quarters and my percent unit growth was more than triple my CV team’s in that same time frame…

the real problem is, our territories don’t line up 100%, so if you (as a CV rep) overlap with 2-3 ISS reps, you blame all ISS reps as being awful when PCP doesn’t perform… same thing happens on ISS team, when we overlap w 2-3 CV territories, we blame all CV reps when the cardiologists don’t perform. Truth is, there are pockets where both teams are doing well and both teams could improve… If Amgen were smart, they would fix this issue and not have territory maps looking like Venn Diagrams, that would increase accountability significantly. But then again, no one wants that here, everyone wants a back pocket excuse when they don’t do well rather than owning it. That’s the real problem.
Click to expand...


you are the exception.

I agree with the other person who posted. ISS is carried by cardiology reps for Repatha, and ISS is carried by NuBu reps with Aimovig.
 
















If you add up the volume growth from the ISS portfolio in PC it exceeds that from Red or NUBU. It’s 3 brands…..but it exceeds CV and NUBU nonetheless. Go cry to your manager and hug it out.
 
















anonymous said:
If you add up the volume growth from the ISS portfolio in PC it exceeds that from Red or NUBU. It’s 3 brands…..but it exceeds CV and NUBU nonetheless. Go cry to your manager and hug it out.
Click to expand...

Neuros and cardiologists prescribe the drugs and you are not the primary reps selling. You get paid for what we in specialty do!!!!! Esp. with Aimovig. you sell nothing! NuBu does it all
 




anonymous said:
Neuros and cardiologists prescribe the drugs and you are not the primary reps selling. You get paid for what we in specialty do!!!!! Esp. with Aimovig. you sell nothing! NuBu does it all
Click to expand...

idiots, you clearly don’t realize that ISS reps IC plan put 80% weighting on PCP performance. Your dumb specialists only contribute 20% to our total performance, regardless of how well you think you do compared to us… we carry three brands and it’s alot to juggle but we kick the CV teams asses… it’s a wonder they even have CV anymore after the HF drug Debacle… should just be KAM’s and ISS… wouldn’t change the numbers much… bet that strikes a nerve
 




anonymous said:
idiots, you clearly don’t realize that ISS reps IC plan put 80% weighting on PCP performance. Your dumb specialists only contribute 20% to our total performance, regardless of how well you think you do compared to us… we carry three brands and it’s alot to juggle but we kick the CV teams asses… it’s a wonder they even have CV anymore after the HF drug Debacle… should just be KAM’s and ISS… wouldn’t change the numbers much… bet that strikes a nerve
Click to expand...

Ha! Yes!!! All CV does is spend $1,000 per virtual lunch to speak to one mid-level for 2 minutes out of 20 providers a few times a week. I’m sure those offices will really miss that level of customer service, dip shits!!
 




Top Bottom
Back
Quote